Health · 59 views
Combination therapy improves progression-free survival for patients with metastatic dMMR colorectal cancer
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab (Tecentriq)…
Summary
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab (Tecentriq) plus modified FOLFOX6 and bevacizumab (Avastin), compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published in the Journal of Clinical Oncology . The combination also produced higher response rates and substantially reduced primary disease progression.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Bayer reaches Roundup settlement that could cost the company billionsContinue reading
- New structures come into view in brain wiring mapsContinue reading
- Cigarettes on silver platters at Bondi ‘clean’ beauty business lip gloss launch referred for investigationContinue reading
- Stress and anxiety are wearing workers down: How to spot your triggers and copeContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow